The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Upadacitinib Receives Breakthrough Designation, Abatacept Use Expands in Australia & More

Upadacitinib Receives Breakthrough Designation, Abatacept Use Expands in Australia & More

January 31, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food and Drug Administration (FDA) has designated upadacitinib a breakthrough therapy to treat adults with moderate to severe atopic dermatitis. In Australia, abatacept was approved to treat adults with active psoriatic arthritis. And the FDA has requested more information about CAM2038, an investigational subcutaneous depot injection of buprenorphine designed to treat adults with opioid use disorder.

You Might Also Like
  • Abatacept Approved for Adult PsA
  • Upadacitinib at the FDA
  • Tocilizumab Designated as Breakthrough Therapy for GCA
Also By This Author
  • FDA Investigates MRI Safety after Studies Find GBCA Deposits in Brain

Upadacitinib Receives Breakthrough Designation
In early January, the FDA designated upadacitinib a breakthrough therapy.1 The treatment is an oral, once daily JAK1-selective inhibitor being investigated for use in adults with moderate to severe atopic dermatitis who are candidates for systemic therapy. The FDA designation for upadacitinib was supported by positive Phase 2b clinical trial results.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Phase 3 program for upadacitinib is planned for the first half of this year.

Abatacept Receives 3rd Australian Approval
The Australian Therapeutic Goods Administration (TGA) has approved abatacept (Orencia) to treat adults for active psoriatic arthritis (PsA) when their response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Abatacept inhibits T cell activation. This approval is the treatment’s third indication from TGA, which include rheumatoid arthritis and juvenile idiopathic arthritis.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

An Injectable Buprenorphine Depot
CAM2038 is an investigational subcutaneous depot injection of buprenorphine given weekly or monthly to treat adults with opioid use disorder. It is designed to be used as part of a comprehensive treatment plan for addiction, which includes counseling and psychosocial support.

The FDA has sent the manufacturers of CAM2038 a complete response letter regarding its new drug application. In the letter, the FDA requested additional information to move the application forward. No additional clinical studies are currently being requested. The manufacturer will continue to work toward the approval of CAM2038.3

In seven Phase 1–3 clinical trials, CAM2038 has been evaluated with successful outcomes, as well as during a Phase 3 long-term safety and efficacy study. Mild to moderate injection-site adverse events were the most common reaction, differing from the known safety profile of already available buprenorphine. The investigated dosage forms are in ready-to-use prefilled syringes as once weekly (8–32 mg) and once monthly (64–160 mg) subcutaneous injections.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

CAM2038 is designed for flexible and individualized treatment, for initiation and stabilization to longer-term maintenance therapy, providing sustained buprenorphine release in once weekly and once monthly formulations. It is administered by a healthcare professional to ensure delivery and medication adherence, as well as minimize the potential diversion, risks of misuse and accidental pediatric exposure.

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: abatacept, Addiction, addiction treatment, Australia, buprenorphine, CAM2038, Psoriatic Arthritis, U.S. Food and Drug Administration (FDA), upadacitinib

You Might Also Like:
  • Abatacept Approved for Adult PsA
  • Upadacitinib at the FDA
  • Tocilizumab Designated as Breakthrough Therapy for GCA
  • Abatacept Approved for Psoriatic Arthritis in Adults; Sirukumab Approval Stalls

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)